Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Postmenopausal women with a history of breast cancer often suffer from climacteric symptoms
such as hot flushes and sweating episodes. Conventional hormone therapy is not allowed in
such patients because there are indications that hormones may cause breast cancer to recur.
Tibolone is a steroid with estrogenic, progestogenic and androgenic activity and is
registered for treatment of climacteric complaints. Tibolone has a pharmacologic and clinical
profile that is different from conventional hormones. In contrast to conventional hormones,
tibolone does not increase breast density and causes less breast pain.
The LIBERATE study is a study in which the safety and efficacy of tibolone has been
investigated in postmenopausal women that have been treated for breast cancer.